Key result
Antithrombotic therapy after myocardial infarction is reviewed in the context of 1.1 million annual infarctions in the United States, of which 450,000 are recurrent.
This article reviews antithrombotic therapy after myocardial infarction, highlighting the significant public health burden of recurrent infarctions.
Answers are grounded in this paper and cite their sources.
High recurrence burden after MI demands optimized antithrombotic regimens; extends RCT evidence guiding secondary prevention.
Despite encouraging trends over the past three decades, coronary heart disease remains the leading cause of death in the United States and other industrialized countries. Recent data from the National Center for Health Statistics and the National Heart, Lung, and Blood Institute1 emphasize the full dimensions of this health problem, revealing that nearly 13 million Americans have coronary heart disease and that 7.5 million have had a myocardial infarction. Because there are 1.1 million myocardial infarctions in the United States alone each year and because 450,000 of them represent recurrent infarctions, which carry an inherently greater risk of death and . . .
No takes yet. Share an insight, caveat, or question.
Richard C. Becker (2002) conducted a review in Myocardial infarction. Antithrombotic therapy was evaluated. Antithrombotic therapy after myocardial infarction is reviewed in the context of 1.1 million annual infarctions in the United States, of which 450,000 are recurrent.
Synapse has enriched 10 related papers. Consider them for comparative context: